Ranolazine (dihydrochloride) (Standard)

Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride) . This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Product Specifications

CAS Number

[95635-56-6]

UNSPSC

12352100

Target

Autophagy; Calcium Channel; Reference Standards; Sodium Channel

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Cardiovascular Disease; Cancer

Smiles

O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2.[H]Cl.[H]Cl

Molecular Formula

C24H35Cl2N3O4

Molecular Weight

500.46

References & Citations

[1]Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[2]Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.|[3]Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.